Bernard Barlaam

1.9k citations

40 papers · 822 · h-index 17

Impact in

Organic Chemistry top 10%
- Quinazolinone synthesis and applications
- Synthesis and biological activity
- Synthesis and Biological Evaluation
Oncology top 10%
- HER2/EGFR in Cancer Research

Papers in

Molecular Biology 23
- PI3K/AKT/mTOR signaling in cancer 9
- Chemical Synthesis and Analysis 6
- Protein Kinase Regulation and GTPase Signaling 3
Organic Chemistry 17
- Quinazolinone synthesis and applications 9

Co-authors: Christine Lambert‐van der Brempt (11 shared papers)Richard Ducray (6 shared papers)Donald Ogilvie (6 shared papers)Jason G. Kettle (5 shared papers)Peter Ballard (5 shared papers)Jean Boivin (4 shared papers)Samir Z. Zard (4 shared papers)T. G. C. Bird (1 shared paper)
Journals: Bioorganic & Medicinal Chemistry Letters (14 papers)Cancer Research (4 papers)Tetrahedron Letters (4 papers)Tetrahedron (3 papers)Journal of Medicinal Chemistry (3 papers)
Partner nations: United Kingdom France United States

In The Last Decade

Bernard Barlaam

38 papers receiving 792 citations

Peers

Countries citing papers authored by Bernard Barlaam

Since Specialization

Citations

This map shows the geographic impact of Bernard Barlaam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernard Barlaam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernard Barlaam more than expected).

Fields of papers citing papers by Bernard Barlaam

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernard Barlaam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernard Barlaam. The network helps show where Bernard Barlaam may publish in the future.

Co-authors

The 25 scholars most cited alongside Bernard Barlaam, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Bernard Barlaam Line = papers co-authored together Bernard Barlaam links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 40 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer Clinical Cancer Research ·D. Mark Hickinson, Teresa Klinowska, Georgina Speake, John P. Vincent, Cath Trigwell, Judith Anderton, Sarah Beck, Gayle Marshall, Sara Davenport, Rowena Callis, Elizabeth Mills, Konstantina Grosios, Paul D. Smith, Bernard Barlaam, Robert W. Wilkinson, Donald Ogilvie	2010	96
2	New α-Substituted Succinate-Based Hydroxamic Acids as TNFα Convertase Inhibitors Journal of Medicinal Chemistry ·Bernard Barlaam, T. G. C. Bird, Christine Lambert‐van der Brempt, Douglas A. Campbell, Steve J. Foster, Rose A. Maciewicz	1999	73
3	Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors Bioorganic & Medicinal Chemistry Letters ·Richard Ducray, Peter Ballard, Bernard Barlaam, Mark Hickinson, Jason G. Kettle, Donald Ogilvie, Catherine B. Trigwell	2007	70
4	Discovery of (R)-8-(1-(3,5-Difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): A Potent and Selective Inhibitor of PI3Kβ and PI3Kδ for the Treatment of PTEN-Deficient Cancers Journal of Medicinal Chemistry ·Bernard Barlaam, Sabina Cosulich, Sébastien L. Degorce, Martina Fitzek, Stephen Green, Urs J. Hancox, Christine Lambert‐van der Brempt, Jean‐Jacques Lohmann, Mickaël Maudet, Rémy Morgentin, Marie‐Jeanne Pasquet, Aurélien Peru, Patrick A. Plé, Twana Saleh, Michel Vautier, Mike Walker, Lara Ward, Nicolas Warin	2014	66
5	Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase Journal of Medicinal Chemistry ·Sébastien L. Degorce, Bernard Barlaam, Elaine Cadogan, Allan Dishington, Richard Ducray, Steven C. Glossop, Lorraine Hassall, Franck Lach, Alan Lau, Thomas M. McGuire, Thorsten Nowak, Gilles Ouvry, Kurt G. Pike, Andrew Thomason	2016	56
6	Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL -rearranged AML Science Signaling ·Isabel Morgado-Palacin, Amanda Day, Matilde Murga, Vanesa Lafarga, Marta Elena Antón, Anthony Tubbs, Hua-Tang Chen, Aysegul V. Ergen, Rhonda Anderson, Avinash Bhandoola, Kurt G. Pike, Bernard Barlaam, Elaine Cadogan, Xi Wang, Andrew J. Pierce, Chad Hubbard, Scott A. Armstrong, André Nussenzweig, Óscar Fernández-Capetillo	2016	48
7	Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors ACS Medicinal Chemistry Letters ·Bernard Barlaam, Judith Anderton, Peter Ballard, Robert H. Bradbury, Laurent Hennequin, D. Mark Hickinson, Jason G. Kettle, George Kirk, Teresa Klinowska, Christine Lambert‐van der Brempt, Cath Trigwell, John P. Vincent, Donald Ogilvie	2013	31
8	Inhibitors of the tyrosine kinase EphB4. Part 3: Identification of non-benzodioxole-based kinase inhibitors Bioorganic & Medicinal Chemistry Letters ·Catherine Bardelle, Bernard Barlaam, Nigel Brooks, Tanya Coleman, Darren A.E. Cross, Richard Ducray, Isabelle Green, Christine Lambert‐van der Brempt, Annie Olivier, Jon Read	2010	30
9	New hydroxylamines for the synthesis of hydroxamic acids Tetrahedron Letters ·Bernard Barlaam, A. Hamon, Mickaël Maudet	1998	26
10	Inhibitors of the tyrosine kinase EphB4. Part 4: Discovery and optimization of a benzylic alcohol series Bioorganic & Medicinal Chemistry Letters ·Bernard Barlaam, Richard Ducray, Christine Lambert‐van der Brempt, Patrick A. Plé, Catherine Bardelle, Nigel Brooks, Tanya Coleman, Darren A.E. Cross, Jason G. Kettle, Jon Read	2011	26
11	New heterocyclic analogues of 4-(2-chloro-5-methoxyanilino)quinazolines as potent and selective c-Src kinase inhibitors Bioorganic & Medicinal Chemistry Letters ·Bernard Barlaam, Mike Fennell, Hervé Germain, Tim Green, Laurent Hennequin, Rémy Morgentin, Annie Olivier, Patrick A. Plé, Michel Vautier, Gerard Costello	2005	23
12	Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase Bioorganic & Medicinal Chemistry Letters ·Peter Ballard, Bernard Barlaam, Robert H. Bradbury, Allan Dishington, Laurent Hennequin, D. Mark Hickinson, Ian Hollingsworth, Jason G. Kettle, Teresa Klinowska, Donald Ogilvie, Stuart E. Pearson, James S. Scott, Abid Suleman, Robin Whittaker, Emma Williams, Robin Wood, Lindsay Wright	2007	23
13	Solid-phase synthesis of hydroxamic acid based TNF-α convertase inhibitors Tetrahedron ·Bernard Barlaam, Patrice Koza, Julien Berriot	1999	22
14	Discovery of a Series of 3-Cinnoline Carboxamides as Orally Bioavailable, Highly Potent, and Selective ATM Inhibitors ACS Medicinal Chemistry Letters ·Bernard Barlaam, Elaine Cadogan, Andrew D. Campbell, Nicola Colclough, Allan Dishington, Stephen T. Durant, Kristin Goldberg, Lorraine Hassall, Gareth Hughes, Philip A. MacFaul, Thomas M. McGuire, Martin Pass, Anil S. Patel, Stuart E. Pearson, Jens Petersen, Kurt G. Pike, Graeme R. Robb, Natalie Stratton, Guohong Xin, Baochang Zhai	2018	21
15	Discovery of 9-(1-phenoxyethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as oral PI3Kβ inhibitors, useful as antiplatelet agents Bioorganic & Medicinal Chemistry Letters ·Fabrizio Giordanetto, Bernard Barlaam, Susanne Berglund, K. A. P. Edman, Olle Karlsson, Jan Lindberg, Sven Nylander, Tord Inghardt	2014	20
16	A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase Bioorganic & Medicinal Chemistry Letters ·Bernard Barlaam, Peter Ballard, Robert H. Bradbury, Richard Ducray, Hervé Germain, D. Mark Hickinson, Kevin Hudson, Jason G. Kettle, Teresa Klinowska, Françoise Magnien, Donald Ogilvie, Annie Olivier, Stuart E. Pearson, James S. Scott, Abid Suleman, Cath Trigwell, Michel Vautier, Robin Whittaker, Robin Wood	2007	18
17	Discovery of 9-(1-anilinoethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours Bioorganic & Medicinal Chemistry Letters ·Bernard Barlaam, Sabina Cosulich, Sébastien L. Degorce, Martina Fitzek, Fabrizio Giordanetto, Stephen Green, Tord Inghardt, Laurent Hennequin, Urs J. Hancox, Christine Lambert‐van der Brempt, Rémy Morgentin, Sarah L. Pass, Patrick A. Plé, Twana Saleh, Lara Ward	2014	17
18	An expedient total synthesis of (±)-estrone derivatives Tetrahedron Letters ·Bernard Barlaam, Jean Boivin, Laurent El Kaïm, Samir Z. Zard	1991	16
19	Addition of Fluorine and a Late-Stage Functionalization (LSF) of the Oral SERD AZD9833 ACS Medicinal Chemistry Letters ·James S. Scott, Tom Moss, Bernard Barlaam, Paul R. J. Davey, Gary Fairley, Eric T. Gangl, Ryan Greenwood, Holia Hatoum‐Mokdad, Andrew Lister, David Longmire, Radosław Polański, S.P. Stokes, Michael Tucker, Jeffrey Varnes, Bin Yang	2020	13
20	A short total synthesis of estrone derivatives: A novel 1,3-rearrangement of an allylic nitro group Tetrahedron ·Bernard Barlaam, Jean Boivin, Laurent El Kaïm, Sarah Elton-Farr, Samir Z. Zard	1995	12

About Bernard Barlaam

Bernard Barlaam is a scholar working on Molecular Biology, Organic Chemistry, Oncology, Genetics and Pulmonary and Respiratory Medicine, having authored 40 papers that have together received 822 indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (9 papers), Quinazolinone synthesis and applications (9 papers), HER2/EGFR in Cancer Research (6 papers), Chemical Synthesis and Analysis (6 papers), Chronic Lymphocytic Leukemia Research (5 papers), Monoclonal and Polyclonal Antibodies Research (3 papers), Protein Kinase Regulation and GTPase Signaling (3 papers) and Peptidase Inhibition and Analysis (3 papers). The work is most often cited by research in Organic Chemistry (305 citations), Oncology (242 citations), Molecular Biology (437 citations), Genetics (56 citations) and Hematology (50 citations). Bernard Barlaam has collaborated with scholars based in United Kingdom, France and United States. Frequent co-authors include Christine Lambert‐van der Brempt, Richard Ducray, Donald Ogilvie, Jason G. Kettle, Peter Ballard, Jean Boivin, Samir Z. Zard, T. G. C. Bird, Douglas A. Campbell and Rose A. Maciewicz. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Cancer Research, Tetrahedron Letters, Tetrahedron and Journal of Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Bernard Barlaam

Impact in

Papers in i

In The Last Decade

Bernard Barlaam

Peers

Countries citing papers authored by Bernard Barlaam

Fields of papers citing papers by Bernard Barlaam

All Works

About Bernard Barlaam

Explore authors with similar magnitude of impact

Papers in